Molina Healthcare Inc

Historical 13F Holders

Symbol
MOH
CUSIP
60855R100
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 60855R100 since 12/18/2024, newest first.

Filer % of Class Filed
Lingotto Investment Management LLP 13G
5.2% 9/3/2026
Event 8/28/2026
AQR Capital Management, LLC 13G/A Amendment 1
6.8% 8/13/2026
Event 6/30/2026
Capital World Investors 13G/A Amendment 14 4.9% 8/12/2026
Event 6/30/2026
FMR LLC 13G/A Amendment 1
3.6% 8/6/2026
Event 6/30/2026
AQR Capital Management, LLC 13G
5.5% 5/14/2026
Event 3/31/2026
Vanguard Capital Management LLC 13G 5.2% 4/30/2026
Event 3/31/2026
Vanguard Portfolio Management LLC 13G 5.4% 4/29/2026
Event 3/31/2026
BlackRock, Inc. 13G/A Amendment 13 11.7% 4/7/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 11 0% 3/27/2026
Event 3/13/2026
Price T Rowe Associates Inc /MD/ 13G/A Amendment 1 1.9% 2/17/2026
Event 12/31/2025
Capital World Investors 13G/A Amendment 13 6.8% 2/13/2026
Event 12/31/2025
AQR Capital Management, LLC 13G/A Amendment 1
0.8% 2/12/2026
Event 12/31/2025
FMR LLC 13G
5.8% 2/5/2026
Event 12/31/2025
BlackRock, Inc. 13G/A Amendment 12 6.9% 1/21/2026
Event 12/31/2025
AQR Capital Management, LLC 13G
5.4% 11/14/2025
Event 9/30/2025
Price T Rowe Associates Inc /MD/ 13G 6.5% 11/14/2025
Event 9/30/2025
Price T Rowe Associates Inc /MD/ 13G/A Amendment 1 4.1% 8/14/2025
Event 6/30/2025
Capital Research Global Investors 13G/A Amendment 1 4.0% 8/13/2025
Event 6/30/2025
Price T Rowe Associates Inc /MD/ 13G 7.0% 5/14/2025
Event 3/31/2025
Price T Rowe Associates Inc /MD/ 13G/A Amendment 2 4.6% 2/14/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 13 23.6 k $4.35 M
2026 Q2 638 70.1 M $12.9 B
2026 Q1 558 55.3 M $7.38 B
2025 Q4 593 54.7 M $9.47 B
2025 Q3 666 57.1 M $11.0 B
2025 Q2 653 53.7 M $15.9 B
2025 Q1 645 53.9 M $17.7 B
2024 Q4 675 53.3 M $15.5 B
2024 Q3 657 56.5 M $19.4 B
2024 Q2 679 60.2 M $17.9 B
2024 Q1 666 59.3 M $24.3 B
2023 Q4 646 59.1 M $21.3 B
2023 Q3 604 58.6 M $19.5 B
2023 Q2 591 58.5 M $17.6 B
2023 Q1 602 57.2 M $15.3 B
2022 Q4 623 59.2 M $19.6 B
2022 Q3 596 56.1 M $18.5 B
2022 Q2 561 56.1 M $15.7 B
2022 Q1 554 56.5 M $18.9 B
2021 Q4 521 54.8 M $17.4 B
2021 Q3 459 55.5 M $15.1 B
2021 Q2 469 55.5 M $14.1 B
2021 Q1 454 55.7 M $13.0 B
2020 Q4 436 56.1 M $12.0 B
2020 Q3 433 57.4 M $10.5 B
2020 Q2 425 59.0 M $10.5 B
2020 Q1 343 62.6 M $8.75 B
2019 Q4 355 66.0 M $8.96 B
2019 Q3 354 61.1 M $6.70 B
2019 Q2 402 61.7 M $8.82 B
2019 Q1 381 63.4 M $8.99 B
2018 Q4 364 66.9 M $7.78 B
2018 Q3 364 70.3 M $10.4 B
2018 Q2 314 72.8 M $7.13 B
2018 Q1 273 71.9 M $5.97 B
2017 Q4 277 63.4 M $4.86 B
2017 Q3 250 60.4 M $4.14 B
2017 Q2 275 55.5 M $3.84 B
2017 Q1 254 54.2 M $2.47 B
2016 Q4 282 52.9 M $2.87 B
2016 Q3 288 51.3 M $2.99 B
2016 Q2 276 50.1 M $2.51 B
2016 Q1 284 49.5 M $3.19 B
2015 Q4 297 51.8 M $3.12 B
2015 Q3 311 49.1 M $3.38 B
2015 Q2 283 47.5 M $3.34 B
2015 Q1 238 41.0 M $2.76 B
2014 Q4 202 39.1 M $2.09 B
2014 Q3 206 38.0 M $1.61 B
2014 Q2 202 37.8 M $1.69 B
2014 Q1 176 35.1 M $1.32 B